Source: https://patents.justia.com/patent/10179187
Timestamp: 2019-12-10 11:39:11
Document Index: 283082507

Matched Legal Cases: ['Application No. 61', 'Application No. 201410471833', 'Application No. 10', 'Application No. 201410471833', 'Application No. 14180732', 'Application No. 14180732', 'application No. 2013204366', 'Application No. 13160331', 'application No. 10', 'Application No. 2015202025', 'application No. 201080055018', 'Application No. 201410471833', 'Application No. 14180732', 'Application No. 14180732', 'Application No. 14180732']

US Patent for Bioresorbable embolization microspheres Patent (Patent # 10,179,187 issued January 15, 2019) - Justia Patents Search
Justia Patents Having Plural Material ReservoirsUS Patent for Bioresorbable embolization microspheres Patent (Patent # 10,179,187)
Dec 5, 2013 - Regents of the University of Minnesota
This application is a continuation of U.S. application Ser. No. 12/899,238, entitled “BIORESORBABLE EMBOLIZATION MICROSPHERES,” filed Oct. 6, 2010, which claims the benefit of U.S. Provisional Application No. 61/249,194, entitled, “EMBOLIZATION MICROSPHERES,” filed on Oct. 6, 2009, the entire contents of which are incorporated herein by reference.
FIG. 38A-38C are light microscopy images illustrating an example of a control that included human dermal fibroblasts stained with crystal violet. FIG. 38A is an image collected about 3 days after beginning of the fibroblast culture. FIG. 38B is an image collected about 7 days after beginning of the fibroblast culture. FIG. 38C is an image collected about 15 days after beginning of the fibroblast culture.
Microspheres disposed in saline and having wet weight of about 150 mg were added into a 22 mL glass vial. (The microspheres had a dry weight of about 17 mg and were formed from OCMC-II and CCN-III.) Excess saline was removed with a pipette. About 20 mL doxorubicin solution (about 2 mg doxorubicin/mL solution) was formed by dissolving doxorubicin in a saline/hydrochloric acid solution having a pH between about 2.5 and about 4.5 and was added into the vial. An amount of doxorubicin remaining in the loading solution after loading of the microspheres was determined by measuring the absorbance at 482 nm using a Beckman UV-Visible spectrophotometer and comparison to a standard curve constructed from solutions of known concentrations of drug. The maximum loading is between about 0.3 and about 0.7 mg doxorubicin per mg dry microspheres, depending on the size of the microspheres.
1. A material comprising at least one microsphere comprising carboxymethyl chitosan crosslinked with carboxymethyl cellulose, wherein the at least one microsphere comprises a crosslinking density between the carboxymethyl chitosan and the carboxymethyl cellulose that results in a fracture strain of the at least one microsphere between about 70% and about 90%.
2. The material of claim 1, wherein the at least one microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.
3. The material of claim 1, wherein the at least one microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.
4. The material of claim 1, wherein the at least one microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.
5. The material of claim 1, wherein the at least one microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.
6. The material of claim 1, wherein the at least one microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.
7. The material of claim 1, wherein the at least one microsphere further comprises a therapeutic agent.
8. The material of claim 7, wherein the therapeutic agent comprises a chemotherapeutic agent.
9. The material of claim 7, wherein the therapeutic agent comprises at least one positively charged functional group.
10. The material of claim 7, wherein the therapeutic agent comprises at least one of irinotecan, ambroxol, or doxorubicin.
11. The material of claim 7, wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.
12. The material of claim 1, wherein the microsphere is substantially free of a small molecule crosslinking agent.
13. An suspension comprising:
a plurality of microspheres suspended in the solvent, wherein at least one microsphere of the plurality of microspheres comprises carboxymethyl chitosan crosslinked with carboxymethyl cellulose, and wherein the at least one microsphere comprises a crosslinking density between the carboxymethyl chitosan and the carboxymethyl cellulose that results in a fracture strain of the at least one microsphere between about 70% and about 90%.
14. The suspension of claim 13, wherein the solvent comprises a mixture of contrast medium and saline.
15. The suspension of claim 14, wherein the mixture comprises between about 40 vol. % contrast medium and about 60 vol. % saline, and about 50 vol. % contrast medium and about 50 vol. % saline.
16. The suspension of claim 13, wherein the at least one microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.
17. The suspension of claim 13, wherein the at least one microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.
18. The suspension of claim 13, wherein the at least one microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.
19. The suspension of claim 13, wherein the at least one microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.
20. The suspension of claim 13, wherein the at least one microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.
21. The suspension of claim 13, wherein the at least one microsphere further comprises a therapeutic agent.
22. The suspension of claim 21, wherein the therapeutic agent comprises a chemotherapeutic agent.
23. The suspension of claim 21, wherein the therapeutic agent comprises at least one positively charged functional group.
24. The suspension of claim 21, wherein the therapeutic agent comprises at least one of irinotecan, ambroxol, or doxorubicin.
25. The suspension of claim 21, wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.
26. The suspension of claim 13, wherein the at least one microsphere is substantially free of a small molecule crosslinking agent.
27. A method of forming a microsphere, the method comprising:
at least partially oxidizing carboxymethyl cellulose (CMC) to form partially oxidized CMC, wherein the CMC comprises a weight average molecular weight of between about 50,000 grams per mole (g/mol) and about 800,000 g/mol prior to oxidation;
forming an emulsion of partially oxidized CMC, carboxymethyl chitosan (CCN), water, and an oil, wherein the CCN comprises a weight average molecular weight of between about 190,000 g/mol and about 375,000 g/mol; and
mixing the emulsion at a temperature of between about 20° C. and 70° C. for at least about 12 hours to crosslink the CCN with the CMC and form the microsphere, wherein the microsphere comprises a crosslinking density between the carboxymethyl chitosan and the carboxymethyl cellulose that results in a fracture strain of the microsphere between about 70% and about 90%.
28. The method of claim 27, wherein crosslinking the CCN with the CMC to form the embolic microsphere comprises mixing the emulsion at a temperature of about 50° C. for at least about 12 hours.
29. The method of claim 27, wherein at least partially oxidizing CMC to form partially oxidized CMC comprises at least partially oxidizing CMC to form partially oxidized CMC using NaIO4.
30. The method of claim 29, wherein a molar ratio of NaIO4 to CMC at the beginning of the oxidation reaction is between about 0.1:1 and about 0.5:1.
mixing the partially oxidized CMC in a solvent at a concentration of between about 0.005 mg CMC per 1 mL water and about 0.03 mg CMC per 1 mL water to form a first solution; and
mixing the CCN in a solvent at a concentration of between about 0.005 mg CCN per 1 mL water and about 0.03 mg CCN per 1 mL water to form a second solution, and
wherein forming the emulsion of partially oxidized CMC, CCN, water, and the oil comprising mixing the first solution, the second solution, and the oil to form the emulsion of partially oxidized CMC, CCN, water, and the oil.
32. The method of claim 27, wherein the emulsion is substantially free of any small-molecule crosslinking agent.
5635215 June 3, 1997 Boschetti et al.
5648100 July 15, 1997 Boschetti et al.
7407646 August 5, 2008 Laurent et al.
8617132 December 31, 2013 Golzarian et al.
8741351 June 3, 2014 Vogel et al.
8936795 January 20, 2015 Golzarian et al.
20050263916 December 1, 2005 Lanphere et al.
20060105014 May 18, 2006 Cruise
20060165804 July 27, 2006 Lewis
20060199010 September 7, 2006 DiCarlo et al.
20060210635 September 21, 2006 Laurent et al.
20070014831 January 18, 2007 Sung
20070031467 February 8, 2007 Abrahams
20070148768 June 28, 2007 Liao
20070264310 November 15, 2007 Hissong
20080041715 February 21, 2008 Lanphere et al.
20090117196 May 7, 2009 Boschetti
20110142965 June 16, 2011 Walke
20130330292 December 12, 2013 Lei et al.
20140099374 April 10, 2014 Golzarian et al.
20140274954 September 18, 2014 Chellappan et al.
20170273888 September 28, 2017 Weng et al.
1481907 March 2004 CN
1762332 April 2006 CN
1939316 April 2007 CN
101125225 February 2008 CN
101209354 July 2008 CN
1508344 February 2005 EP
1810698 July 2007 EP
2626088 August 2013 EP
2803370 November 2014 EP
2009056602 May 2009 WO
2009072146 June 2009 WO
2011044236 April 2011 WO
2014152488 September 2014 WO
2015033093 March 2015 WO
Liu YF, et al. Preparation and characterization of glutaraldehyde cross-linked O-carboxymethylchitosan microspheres for controlled delivery of pazufloxacin mesilate. Int J Biol Macromol. Jun. 1, 2007;41(1)L87-93.
Second Office Action, and partial translation thereof, from counterpart Chinese Application No. 201410471833.6, dated May 19, 2016, 12 pp.
Office Action, and translation thereof, from counterpart Korean Application No. 10-2013-7034806, dated Oct. 7, 2015, 7 pp.
First Office Action, and partial translation thereof, from counterpart Chinese Application No. 201410471833.6, dated Sep. 22, 2015, 14 pp.
Response to Communication dated Nov. 24, 2014, from counterpart European Patent Application No. 14180732.1, filed May 6, 2015, 7 pp.
Search Report from Counterpart European Patent Application No. 14180732.1, dated Oct. 22, 2014, 7 pp.
Notice of Allowance from U.S. Appl. No. 13/720,135, dated Sep. 4, 2014, 8 pp.
Advisory Action from U.S. Appl. No. 13/720,135, dated May 29, 2014, 4 pp.
Pre-Appeal Brief Request for Review for U.S. Appl. No. 13/720,135, dated Jun. 19, 2014, 5 pp.
Response to Final Office Action from co-pending U.S. Appl. No. 13/720,135, filed Apr. 21, 2014, 10 pp.
Examination Report issued in the corresponding Australian patent application No. 2013204366 dated Feb. 27, 2014. 2 pp.
Final Office Action from the corresponding U.S. Appl. No. 13/720,135, dated Feb. 19, 2014. 11 pp.
Written Opinion and Search Report from corresponding PCT Application No. PCT/US2010/051629, dated Feb. 23, 2011 (11 pp).
Kettenbach et al. “Drug-Loaded Microspheres for the Treatment of Liver Cancer: Review of Current Results”, Cardiovasc Intervent Radiol (Jan. 29, 2008) 31:468-476 (9 pp).
International Preliminary Report on Patentablity from corresponding PCT Application No. PCT/US2010/051629, dated Apr. 19, 2012, 6 pages.
Laurent, “Microspheres and Nonspherical Particles for Embolization,” Techniques in Vascular and Interventional Radiology, vol. 10, No. 4, Dec. 1, 2007, 10 pages.
Ohta et al., “Degradable Gelatin Microspheres as an Embolic Agent: An Experimental Study in a Rabbit Renal Model,” Korean J. Radiol 8(5), Oct. 2007, pp. 418-428.
Nitta et al., “Gelatin Microspheres: Initial Clinical Experience for the Transcatheter Arterial Embolization,” European Journal of Radiology, vol. 67, Issue 3, Sep. 2008, 536-540.
Wang et al., “Preparation and Characterization of Pingyangmycin-loaded Bovine Serum Albumin Microspheres for Embolization Therapy,” International Journal of Pharmaceutics, vol. 336, No. 2, May 24, 2007, pp. 361-366.
Laccourreye et al., “Biodegradable Starch Microspheres for Cerebral Arterial Embolization,” Journal of Clinical and Laboratory Research, vol. 28, No. 2, Feb. 1993, pp. 150-154.
Flandroy et al., “(D,L) Polylactide Microspheres as Embolic Agent,” Neuroradiology, vol. 32, No. 4, Feb. 1990, pp. 311-315.
Wu et al., “Preparation and Drug Release Characteristics of Pingyangmycin-Loaded Dextran Cross-Linked Gelatin Microspheres for Embolizalion Therapy,” Journal of Biomedical Materials Research, Part B, vol. 78B, Issue I, Jul, 2006, 56-62
Liu et al., “A Study of Doxorubicin Loading Onto and Release from Sulfopropyl Dextran Ion-Exchange Microspheres,” Journal of Controlled Release, vol. 77, Dec. 2001, pp. 213-224.
European Search Report from Application No. 13160331.8, dated Jul. 16, 2013, 4 pages.
Office Action from corresponding Korean patent application No. 10-2012-7011638, dated Aug. 7, 2013, 7 pp.
Office Action dated Jul. 22, 2013 for U.S. Appl. No. 13/720,135 (11 pgs.).
Responsive amendment, dated Oct. 22, 2013, for U.S. Appl. No. 13/720,135, 11 pages.
First Examination Report from counterpart Australian Application No. 2015202025, dated Sep. 18, 2015, 2 pp.
Grosso et al., Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study, Cardiovascular Interventional Radiology, vol. 31(6), Aug. 12, 2008, pp. 1141-1149.
Haijun et al., “Effects of Carboxymethylchitosan-carboxymethylcellulose Membrane on Extraneural Adhesion Formation and Peripheral Nerve Regeneration,” Journal of Clinical Rehabilitative Tissue Engineering Research, vol. 13(34), Aug. 20, 2009, 5 pp. (English Translation of Abstract Only.).
English Translation of Chinese Office Action from Chinese counterpart application No. 201080055018.1, dated Jan. 23, 2014, 3 pp.
The Notification of Rejection, and partial translation thereof, from counterpart Chinese Application No. 201410471833.6, dated Sep. 12, 2016, 15 pp.
Barnett et al., “In Vitro Assessment of EmboGel and UltraGel Radiopaque Hydrogels for the Endovascular Treatment of Aneurysms,” Journal of Vascular Interventional Radiology, Apr. 2009, 20:507-512.
Brennecka et al., “In Vivo Experimental Aneurysm Embolization in a Swine Model with a Liquid-to-Solid Gelling polymer System: Initial Biocompatibility and Delivery Strategy Analysis,” World Neurosurgery, Nov. 2012; 78(5):469-80 (Epublished Nov. 1, 2011).
Fatimi et al., “A New Injectable Radiopaque Chitosan-Based Sclerosing Embolizing Hydrogel for Endovascular Therapies,” Acta Biomaterialia, Jul. 2012; 8(7):2712-21 (Epublished Apr. 2012).
International Campaign Against Microbeads in Cosmetics, accessed from www.beatthemicrobead.org on Jul. 2015, 4 pp.
Kazekawa et al., “Newly Synthesized Liquid Embolization Material for Arteriovenous Malformation,” Journal Clinical Neuroscience, Mar. 1998, 45-48 pp.
Ko et al., “Preoperative Portal Vein Embolization with a New Liquid Embolic Agent,” Radiology, May 2003, vol. 227, Vo. 2, 407-413 (Epublished Mar. 13, 2003).
Kutlu et al, “Pulmonary Embolism After Penile Deep Dorsal Vein Embolization with n-butyl-2-cyanoacrylate and Lipiodol Mixture” European Journal Radiology Extra, Mar. 2004, 49(3), 103-106 pp.
Mottu et al., “Iodine-Containing Cellulose Mixed Esters as Radiopaque Polymers for Direct Emoblization of Cerebral Aneurysms and Arteriovenous Malformations,” Biomaterials, Jan. 2002, 23(1), 121-131 pp.
Pollak et al., “The Use of Cyanoacrylate Adhesives in Peripheral Embolization,” Journal of Vascular Interventional Radiology, Aug. 2001,12, 907-913 pp.
Shi et al., “Therapeutic Embolization of Meningiomas with Onyx for Delayed Surgical Resection,” Surgical Neurology, Nov. 2008, 70:478-481 (Epublished Feb. 8, 2008).
Silas et al., “Sclerosis of Postoperative Lymphoceles: Avoidance of Prolonged Catheter Drainage with Use of a Fibrin Sealant,” Journal of Vascular Interventional Radiology, Nov. 2006, 17:1791-1795.
Su et al., “Histopathological Studies of a New Liquid Embolization Method Using Estrogen-Alcohol and Polyvinyl Acetate: Experimental Evaluations with a Model of Cortical Arterial Cannulation in the Canine Brain,” Surgical Neurology, Jul. 1991, vol. 36, No. 1, 4-11 pp.
Weng et al., “Bioresorbable Hydrogel Microspheres for Transcatheter Embolization: Preparation and in Vitro Evaluation,” Laboratory Investigation, Jun. 15, 2011, 9 pp.
Weng et al., “Calibrated Bioresorbable Microspheres as an Embolic Agent: An Experimental Study in a Rabbit Renal Model,” HHS Public Access, PMC Oct. 4, 2016, 15 pp.
Weng et al., “Doxorubicin loading and eluting characteristics of bioresorbable hydrogel microspheres: in vitro study,” International Journal of Pharmaceutics, vol. 409, Issues 1-2, May 16, 2011, 185-193 pp.
Weng et al., “In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release,” Acta Biomaterialia, Elsevier, vol. 9, Issue 6, Jun. 2013, 12 pp.
Weng et al., “In Vitro Assessment of an in Situ Gelable Hydrogel for Adjunct Endovascular Treatment of Abdominal Aortic Aneurysms,” Journal of Vascular and Interventional Radiology, Abstract 346, Mar. 2012, 23(3): S139.
Kim et al., “MRI Visible Drug Eluting Magnetic Microspheres for Transcatheter Intra-Arterial Delivery to Liver Tumors,” Theranostics, vol. 5, Issue 5, Feb. 7, 2015, 12 pp.
Kim et al., “Multimodal Imaging of Nanocomposite Microspheres for Transcatheter Intra-Arterial Drug Delivery to Liver Tumors,” Scientific Reports, Jul. 13, 2016, 10 pp.
Sommer et al., “Multimodal Visibility (Radiography, Computed Tomography, and Magnetic Resonance Imaging) of Microspheres for Transarterial Embolization Tested in Porcine Kidneys,” Investigative Radiology, vol. 48, No. 4, Apr. 2013, 10 pp.
Weng et al., “Synthesis and in vitro evaluation of MRI visible resorable and loadable microspheres for arterial embolization,” Abstract only submitted for the SIR Annual Scientific Meeting, downloaded Jan. 25, 2018, 2 pp.
Examination Report from counterpart European Application No. 14180732.1, dated Apr. 4, 2018, 4 pp.
Response to Extended Search Report dated Apr. 4, 2018, from counterpart European Application No. 14180732.1, filed Jul. 17, 2018, 10 pp.
Notice of Intent to Grant and Text Intended to Grant from counterpart European Application No. 14180732.1, dated Sep. 21, 2018, 85 pp.
Patent Publication Number: 20140099374
Inventors: Jafar Golzarian (Plymouth, MN), Lihui Weng (Woodbury, MN)
Application Number: 14/098,443
International Classification: A61B 19/00 (20060101); A61L 24/08 (20060101); A61L 24/00 (20060101);